Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 4, 2026 | −$0.54 | −130.7% | $16.61B | +5.1% | −$0.26 |
| Q1 FY26ended Mar 31, 2026 | Apr 30, 2026 | −$1.72 | −185.6% | $16.29B | +4.9% | −$1.51 |
| Q4 FY25ended Dec 31, 2025 | — | $1.19 | −19.6% | $16.40B | +5.0% | — |
| Q3 FY25ended Sep 30, 2025 | — | $2.32 | +87.1% | $17.28B | +3.7% | — |
| Q2 FY25ended Jun 30, 2025 | — | $1.76 | −17.8% | $15.81B | −1.9% | — |
| Q1 FY25ended Mar 31, 2025 | — | $2.01 | +7.5% | $15.53B | −1.6% | — |
| Q4 FY24ended Dec 31, 2024 | — | $1.48 | — | $15.62B | +6.8% | — |
| Q3 FY24ended Sep 30, 2024 | — | $1.24 | −33.3% | $16.66B | +4.4% |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Merck shares, not any token. As of Aug 4, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| Q2 FY24ended Jun 30, 2024 | — | $2.14 | — | $16.11B | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $1.87 | — | $15.78B | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$0.48 | — | $14.63B | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $1.86 | — | $15.96B | — | — |